Geneva, Switzerland – September 8, 2026
A two‑drug regimen may finally halt aggressive prostate cancers that escape standard androgen‑targeted therapy by reshaping their cellular identity.
Why This Matters Now
Prostate cancer remains the second leading cause of cancer‑related death among men in the United States. While most tumors initially depend on male hormones and respond to androgen‑receptor blockers, nearly all patients eventually develop resistance, often by a process called transdifferentiation—where cancer cells shed their glandular characteristics and adopt a stem‑like, therapy‑evasive state.
Study Design and Key Findings
The University of Michigan team, led by Dr. Joshi Alumkal, examined prostate cancer cell lines lacking the tumor‑suppressor genes TP53 and RB1, which are known triggers of transdifferentiation. They screened two drug classes:
- BET bromodomain inhibitors – block the transcriptional programs that activate alternative cell identities.
- DNA‑methyltransferase (DNMT) inhibitors – reactivate silenced glandular genes.
When applied individually, each drug modestly slowed cell proliferation but failed to induce cell death. The combination, however, produced a synergistic effect:
- Restored expression of >1,200 glandular‑specific genes.
- Suppressed stem‑like transcriptional signatures.
- Cut tumor growth in mouse xenografts by two‑thirds without observable toxicity.
"When we used both drugs, we reversed a significant portion of gene‑expression changes that occur in the tumors, which is encouraging," said Will Storck, Ph.D., a research specialist in the Alumkal lab.
Expert Commentary
"Targeting both sides of the cellular shift could be more effective than blocking only one pathway," noted Dr. Alumkal, professor of internal medicine‑hematology/oncology at the Rogel Cancer Center. "Preventing transdifferentiation before it happens may be key to patient survival."
Implications and Next Steps
The findings suggest a therapeutic avenue for patients whose cancers have already undergone transdifferentiation, a group with few effective options. The researchers plan to:
- Identify biomarkers that predict which patients will benefit from the combination.
- Test the regimen in early‑phase clinical trials.
- Explore whether the same strategy applies to other cancers that undergo similar identity shifts, such as certain lung and pancreatic tumors.
Sources
- Alumkal, J., Storck, W., et al. Combined BET bromodomain and DNMT inhibition targets critical survival pathways in transdifferentiated prostate cancer. JCI Insight (2026). DOI: 10.1172/jci.insight.207543.
- Michigan Medicine – University of Michigan. Scientists find a new weakness in treatment‑resistant prostate cancer. ScienceDaily, September 8, 2026. .
- National Cancer Institute. Prostate Cancer Statistics. .
FIRAT Editorial Board
Institutional Research Desk · Foresight Institute of Research and Translation
The collective editorial and research translation board of FIRAT, synthesising peer-reviewed evidence, policy briefs, and division milestones across our seven foundational research pillars.
